Abstract
The participation of a specific subset of B cells and how they are regulated in cancer is unclear. Here, we demonstrate that the proportion of CD5(+) relative to interleukin-6 receptor α (IL-6Rα)-expressing B cells was greatly increased in tumors. CD5(+) B cells responded to IL-6 in the absence of IL-6Rα. IL-6 directly bound to CD5, leading to activation of the transcription factor STAT3 via gp130 and its downstream kinase JAK2. STAT3 upregulated CD5 expression, thereby forming a feed-forward loop in the B cells. In mouse tumor models, CD5(+) but not CD5(-) B cells promoted tumor growth. CD5(+) B cells also showed activation of STAT3 in multiple types of human tumor tissues. Thus, our findings demonstrate a critical role of CD5(+) B cells in promoting cancer.
Copyright © 2016 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
B-Lymphocytes / immunology*
-
CD5 Antigens / biosynthesis
-
CD5 Antigens / metabolism*
-
Cell Line, Tumor
-
Cytokine Receptor gp130 / metabolism
-
Humans
-
Interleukin-6 / immunology
-
Interleukin-6 / metabolism*
-
Janus Kinase 2 / metabolism
-
Melanoma, Experimental / pathology*
-
Mice
-
Mice, Inbred C57BL
-
Mice, Knockout
-
NIH 3T3 Cells
-
Protein Binding
-
Receptors, Interleukin-6 / biosynthesis
-
Receptors, Interleukin-6 / genetics
-
Receptors, Interleukin-6 / immunology
-
STAT3 Transcription Factor / immunology*
-
Transcriptional Activation / immunology
Substances
-
CD5 Antigens
-
Cd5 protein, mouse
-
Il6st protein, mouse
-
Interleukin-6
-
Receptors, Interleukin-6
-
STAT3 Transcription Factor
-
Stat3 protein, mouse
-
interleukin-6 receptor alpha
-
Cytokine Receptor gp130
-
Jak2 protein, mouse
-
Janus Kinase 2